Abilify Lawsuits - Law Cost

If you are looking for information about Abilify lawsuits, you have come to the right place. We have covered several different issues including Gambling addiction, Compulsive shopping, birth defects, failure to warn, and failure of Bristol-Myers Squibb to provide adequate warnings. Read on to learn more about the potential risks of Abilify and how to get a free case review. Abilify lawsuits are a great way to get justice for those who have suffered a negative consequence from this drug.

Gambling addiction

If you have been diagnosed with a gambling addiction, you may be wondering if you can pursue legal action against the producer of Abilify. Abilify causes the compulsive behavior, which can lead to significant financial loss. This article will provide you with some insight into how to proceed if you feel that you may have a case. If you think that you have a valid claim, contact an Abilify attorney as soon as possible to get the legal process started.

Many Abilify lawsuits aim to recover compensation for losses sustained from compulsive gambling. This compensation includes lost wages, pain, and suffering, and future medical costs. Some lawsuits also seek punitive damages, which are intended to punish the drug maker for its actions and deter others from taking the drug. In April 2018, however, Otsuka and its lawyers agreed to settle Abilify lawsuits in state and federal courts.

Compulsive shopping

A new lawsuit alleges that a prescription drug for compulsive shopping can cause depression and anxiety. The lawsuits allege that Bristol-Myers Squibb violated state laws by illegally paying doctors to prescribe the medication. Bristol-Myers Squibb has agreed to pay $19.5 million in settlements. However, the lawsuits continue. In July 2017, Bristol-Myers Squibb and Otsuka settled three cases involving Abilify.

Bristol-Myers Squibb, the company that manufactures Abilify, is facing hundreds of lawsuits involving these products. Many of these cases claim that the drug did not adequately warn consumers about compulsive gambling risks, which can cost people thousands of dollars. Fortunately, the drug was marketed widely throughout the United States. Although the side effects of Abilify can be unpleasant, many users did not anticipate them. Several other cases involving compulsive shopping and Abilify are pending in U.S. district courts throughout the country.

Birth defects

Some of the cases involving birth defects and the anti-seizure drug Abilify are a result of the medication’s adverse effects on a baby’s development. For example, a baby who takes Abilify has an increased risk of developing cognitive or behavioral disabilities, while those who take Phenobarbital may develop intellectual disabilities. The symptoms may not be apparent until later in life.

Bristol-Myers Squibb’s failure to warn

A lawsuit filed against Bristol-Myers Squibb and Otsuka America Pharmaceutical alleges that the drug Abilify fails to warn about serious side effects. The drug’s manufacturers failed to warn patients and physicians of the potentially life-threatening side effects of Abilify. As early as 2012, other countries added warnings to Abilify. However, these warnings could have been added much earlier, before the drug became available.

A lawsuit against Bristol-Myers Squibb and Otsuka American Pharmaceutical was filed in New York on behalf of five women who claimed that Abilify caused type 2 diabetes in their children and that the companies failed to warn physicians about these risks. The companies were sued in New York but were unsuccessful in getting any witnesses outside the state. They have agreed to pay over $515 million to settle the case.

Bristol-Myers Squibb’s illegal marketing of Abilify

In a recent civil settlement, Bristol-Myers Squibb has agreed to pay $30 million to resolve a wide range of allegations regarding the company’s illegal marketing of Abilify. The New York-based pharmaceutical company has been accused of improperly marketing the multifaceted treatment for bipolar disorder and depression. This is even though the drug is only approved for the treatment of bipolar disorder and schizophrenia.

The settlement resolves state claims, which are similar to those from the 2007 settlement. The settlement also addresses claims that the drug was illegally marketed and used for unapproved purposes in children. The settlement has been centralized in the U.S. District Court for the Northern District of Florida. Despite the initial settlement, the ongoing litigation could prove to be much more expensive than the previous settlements.